Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Ligand Pharmaceuticals Incorporated

Biopharma Cost Trends: A Decade of Change

__timestampIntra-Cellular Therapies, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014212263459136000
Thursday, January 1, 20151396265807000
Friday, January 1, 2016938315305571000
Sunday, January 1, 2017794190095366000
Monday, January 1, 20183686736337000
Tuesday, January 1, 201947712111347000
Wednesday, January 1, 2020189502930419000
Friday, January 1, 2021803458962176000
Saturday, January 1, 20222044300052827000
Sunday, January 1, 20233374500035049000
Loading chart...

Unlocking the unknown

A Decade of Cost Dynamics in Biopharmaceuticals

In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, Intra-Cellular Therapies, Inc. and Ligand Pharmaceuticals Incorporated have showcased intriguing trends in their cost of revenue. From 2014 to 2023, Intra-Cellular Therapies experienced a dramatic surge, with costs peaking in 2016 at nearly 90% higher than their 2014 levels. Meanwhile, Ligand Pharmaceuticals saw a more consistent rise, with a notable 500% increase from 2014 to 2021. This divergence highlights the varying strategies and market conditions faced by these companies. While Intra-Cellular's costs fluctuated, Ligand's steady climb suggests a more stable operational model. As the industry continues to innovate, these insights offer a glimpse into the financial strategies shaping the future of biopharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025